Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis (Q37859111)

24 August 2017

1 reference

title

Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis (English)

1 reference

24 August 2017

1 reference

1 reference

J Niles

1

1 reference

24 August 2017

publication date

1 May 2011

1 reference

Clinical and Experimental Immunology

24 August 2017

published in

1 reference

24 August 2017

volume

164 Suppl 1

1 reference

24 August 2017

page(s)

27-30

1 reference

Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Pathophysiology of ANCA-Associated Small Vessel Vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Rituximab treatment results in impaired secondary humoral immune responsiveness.

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095862

Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies.

1 October 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095862

Wegener's granulomatosis: studies in eighteen patients and a review of the literature

1 October 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095862

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

1 October 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2011.04363.X

Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion

21 January 2018

1 reference

12 December 2020

Association between active Wegener's granulomatosis and anticytoplasmic antibodies

1 reference

12 December 2020

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies

1 reference

12 December 2020

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs

1 reference

12 December 2020

Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis

1 reference

12 December 2020

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

12 December 2020

10.1111/J.1365-2249.2011.04363.X

Identifiers

DOI

1 reference

24 August 2017

0 references

1 reference